Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc has enhanced its financial stability through recent equity financings and option exercises, indicating a strengthened position in anticipation of significant revenue growth that is expected to materialize starting in 2026. The company's financing income has notably improved, rising to $284,000 for the quarter and $611,000 year-to-date, reflecting successful financial management and higher earnings from marketable securities. Furthermore, with the establishment of a comprehensive go-to-market infrastructure and positive market feedback on its LIBERTY Endovascular Robotic Surgical System, Microbot is well-prepared for a successful product launch in the U.S. and Europe, fostering a promising outlook for sustained growth in the coming years.

Bears say

Microbot Medical Inc faces several significant risks that contribute to a negative outlook, including potential delays in commercialization and challenges in expanding its product offerings into neurological and cardiovascular segments. The company has yet to achieve profitability and may contend with reimbursement headwinds that could further strain financial performance, coupled with the pressure of device costs eroding hospital margins. Additionally, the lack of robust clinical data from randomized controlled trials poses a substantial risk to the adoption rates of the LIBERTY Endovascular Robotic Surgical System, potentially hindering overall market penetration.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.